N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: In vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice

British Journal of Cancer

Volumn 96, Issue 11, 2007, Pages 1684-1691

  Borel, M ^a,b,c   Degoul, F ^a,b,c   Communal, Y ^a,b,c   Mounetou, E ^a,b,c   Bouchon, B ^a,b,c   C Gaudreault, R ^d   Madelmont, J C ^a,b,c   Miot Noirault, E ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CENTRE JEAN PERRIN   (France)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

1H HRMAS NMR; Colon carcinoma; CT 26; Phospholipids; Tubulin; Uptake

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; CARBENE; N (4 IODOPHENYL) N' (2 CHLOROETHYL)UREA; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; LIPID MEMBRANE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED BALB C; MICROTUBULES; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; PHENYLUREA COMPOUNDS; PHOSPHOLIPIDS; TUBULIN; TUBULIN MODULATORS;

EID: 34249780124     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603778     Document Type: Article

References (33)

1. Bechard P, Lacroix J, Poyet P, C-Gaudreault R (1994) Synthesis and cytotoxic activity of new alkyl[3-(2-chloroethyl)ureido]benzene derivatives. Eur J Med Chem 29: 963-966
2. Bezabeh T, Mowat MRA, Jarolim L, Greenberg AH, Smith ICP (2001) Detection of drug-induced apoptosis and necrosis in human cervical carcinoma cells using 1H NMR spectroscopy. Cell Death Differ 8: 219-224
3. Blankenberg FG, Katsikis PD, Storrd RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF (1997) Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 89: 3778-3786
4. Blankenberg FG, Storrs RW, Naumovski L, Goralski T, Spielman D (1996) Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 87: 1951-1956
5. Bouchon B, Chambon C, Mounetou E, Papon J, Miot-Noirault E, Gaudreault RC, Madelmont JC, Degoul F (2005) Alkylation of β-tubulin on Glu 198 by a microtubule disrupter. Mol Pharmacol 68: 1415-1422
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
7. 1H NMR visible mobile lipids during apoptosis of paclitaxel-treated K562 cells. Biochem Pharmacol 65: 1271-1280
8. Cabral F (2001) Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist Update 4: 3-8
9. Drukman S, Kavallaris M (2002) Microtubule alterations and resistance to tubulin-binding agents. Int J Oncol 21: 621-628
10. Gaudreault RC, Lacroix J, Page M, Joly LP (1988) Synthesis and in vitro assay of 1-aryl 3-(2-chloroethyl) ureas as potential anticancer agents. J Pharm Sci 77: 185-188
11. Kamm YJL, Peters GJ, Hull WE, Punt CJA, Heerschap A (2003) Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer 89: 754-762
12. Krysko DV, D'Herde K, Vandenabeele P (2006) Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 11: 1709-1726
13. Labarre P, Papon J, Moreau MF, Moins N, Veyre A, Madelmont JC (1999) Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multiwire proportional counting. Eur J Nucl Med 26: 494-498
14. Lacroix J, C-Gaudreault R, Page M, Joly LP (1988) In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic agents. Anticancer Res 8: 595-598
15. Legault J, Gaulin JF, Mounetou E, Bolduc S, Lacroix J, Poyet P, Gaudreault RC (2000) Microtubule disruption induced in vivo by alkylation of β-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res 60: 985-992
16. Lindskog M, Spenger C, Jarvet J, Graslund A, Kogner P (2004) Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma. J Natl Cancer Inst 96: 1457-1466
17. Liu G, Wu C, Wu Y, Zhao Y (2006) Phagocytosis of apoptotic cells and immune regulation. Scand J Immunol 64: 1-9
18. McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, Robinson SP (2005) Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11: 3705-3713
19. Miot-Noirault E, Legault J, Cachin F, Mounetou E, Degoul F, Gaudreault RC, Moins N, Madelmont JC (2004) Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma. Invest New Drugs 22: 369-378
20. Mounetou E, Legault J, Lacroix J, Gaudreault RC (2001) Antimitotic antitumour agents: synthesis, structure-activity relationships and biological characterization of N-aryl-N-(2-chloroethyl)ureas as new selective alkylating agents. J Med Chem 44: 694-702
21. Mounetou E, Legault J, Lacroix J, Gaudreault RC (2003) A new generation of N-aryl-N_-(1-alkyl-2-chloroethyl)ureas as microtubule disrupters: synthesis, antiproliferative activity and beta-tubulin alkylation kinetics. J Med Chem 46: 5055-5063
22. Petitclerc E, Deschesnes RG, Cote MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, Gaudreault RC (2004) Antiangiogenic and antitumoural activity of phenyl-3-(2-chloroethyl) ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res 64: 4654-4663
23. Saint-Laurent A, Boudreau N, Lariviere D, Legault J, Gaudreault RC, Auger M (2001) Membrane interactions of a new class of anticancer agents derived from arylchloroethylurea: a FTIR spectroscopic study. Chem Phys Lipids 111: 163-175
24. Sapan CV, Lundblad RL, Price NC (1999) Colorimetric protein assay techniques. Biotechnol Appl Biochem 29: 99-108
25. Schimming R, Mason KA, Hunter N, Weil M, Kishi K, Milas L (1999) Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother Pharmacol 43: 165-172
26. Singer WD, Himes RH (1992) Cellular uptake and tubulin binding properties of four Vinca alkaloids. Biochem Pharmacol 43: 545-551
27. Sitter B, Sonnewald U, Spraul M, Fjösne HE, Gribbestad IS (2002) Highresolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 15: 327-337
28. 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma. NMR Biomed 18: 252-259
29. Wang Y, Tian G, Cowan NJ, Cabral F (2006) Mutations affecting β-tubulin folding and degradation. J Biol Chem 281: 13628-13635
30. Weaver BA, Cleveland DW (2005) Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8: 7-12
31. 1H nuclear magnetic resonance spectroscopy of intact cells. Magn Reson Med 39: 337-345
32. Wilson L, Jordan MA (2004) New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J Chemother 16(Suppl 4): 83-85
33. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd ed.). Br J Cancer 77: 1-10